Uncategorized
Aldeyra announces positive results from dry eye treatment trial
A phase 2a clinical trial of topical ocular ADX-102 in patients with dry eye disease showed significant improvements across several sign and symptom endpoints, according to a press release from Aldeyra Therapeutics. The randomized, dose-ranging, parallel-group, double-masked trial studied three formulations of ADX-102 in 51 patients: 0.1% ophthalmic solution, 0.5% ophthalmic solution and 0.5% lipid formulation.